Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) FCF Margin (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed FCF Margin for 15 consecutive years, with 183.04% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 6323.0% to 183.04% in Q3 2025 year-over-year; TTM through Sep 2025 was 300.59%, a 10296.0% decrease, with the full-year FY2024 number at 184.51%, up 8032.0% from a year prior.
  • FCF Margin was 183.04% for Q3 2025 at Plus Therapeutics, up from 417.63% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1545.0% in Q1 2021 to a low of 5828.77% in Q3 2022.
  • A 5-year average of 692.09% and a median of 223.51% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 562802bps in 2023, then tumbled -32138bps in 2025.
  • Plus Therapeutics' FCF Margin stood at 1545.0% in 2021, then plummeted by -220bps to 1859.84% in 2022, then soared by 92bps to 146.46% in 2023, then soared by 39bps to 89.8% in 2024, then tumbled by -104bps to 183.04% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's FCF Margin are 183.04% (Q3 2025), 417.63% (Q2 2025), and 583.1% (Q1 2025).